Genetic Analysis

The Chinese direct-to-consumer (D2C) microbiome testing market is experiencing rapid growth, with an estimated market size of USD 50-80 million in 2023 and a projected compound annual growth rate (CAGR) of 20-30%, potentially reaching USD 200-300 million by 2030. This growth is driven by increased consumer interest in gut health, probiotics, personalized nutrition, and advancements in e-commerce and digital health platforms like Tmall and WeChat. Thalys is launching a microbiome testing service in China using the GA-map® Dysbiosis Test, offering consumers a fast and affordable way to assess gut health. The service includes a mobile app for customers to subscribe, pay, and view results, providing insights into gut microbes and personalized health recommendations. This launch marks the first stage of a collaboration between Thalys and Genetic Analysis, with plans for further development and distribution of tests in China. The partnership involves Thalys investing in clinical studies and software development, while Genetic Analysis provides reagent kits and proprietary software. The collaboration is structured as an ongoing partnership without predefined order volumes, generating revenue for Genetic Analysis based on the number of tests sold. Thalys Group, a leading provider of medical supply chain management and IVD solutions in China, aims to be an innovative and trusted partner in healthcare. Genetic Analysis is a diagnostic company specializing in the human microbiome, with a vision to lead standardized gut microbiota testing worldwide.

Genetic Analysis (GA), under CEO Ronny Hermansen, reported record sales in Q4 2024, with a 63% increase compared to the previous year, reaching NOK 6.2 million. The company achieved its first positive EBITDA of NOK 0.4 million, marking a significant milestone. The GA-map® Dysbiosis Test sales grew 49% in Q4 and 37% YTD. A major agreement with Ferring Pharmaceuticals was signed to develop a new microbiome-based diagnostic test, targeting a launch in H1 2025. Financial highlights include an operating income of NOK 7.3 million in Q4, with a net loss of NOK 0.9 million. Operating costs decreased by 37% in Q4, attributed to reduced R&D expenses and general cost cuts. Significant events included share purchases by GA’s Head of Operations and CEO, and a collaboration with Ferring Pharmaceuticals to develop a new PCR test. No significant events were reported after the period. GA aims to lead in standardized gut microbiota testing globally.